Sponsor:
Tasso Inc.
Code:
NCT05259618
Conditions
Elevated Alanine Transaminase (ALT)
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Interventions
Tasso+ SST
Brief summary:
Conditions
Elevated Alanine Transaminase (ALT)
Study ID
NCT05259618
Start date
Feb 16, 2021
Status verified date
Feb, 2022
Completion date
Nov, 2022
Anticipated
Primary completion date
Nov, 2022
Anticipated
Eligibility Criteria
Sex: All
Age: 18+
Healthy Volunteers: Not accepted
Enrollment
80 participants
Anticipated
Arms
Patients with elevated alanine transaminase (ALT)
Interventions
Tasso+ SST
Primary outcome measure
Central contacts
Locations
Memorial Sloan Kettering Cancer Center
Recruiting
New York, New York, United States, 10017
Contacts
Principal Investigator:
James J Harding, MD
EvergreenHealth Research
Recruiting
Kirkland, Washington, United States, 98034
Contacts
Principal Investigator:
Diego Lopez de Castilla, MD
Sponsor
Tasso Inc.
Last update posted
Feb 28, 2022
Last verified
Feb, 2022
Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Tasso Inc. on 2022-02-28.